{'fraction_non_alphanumeric': 0.03424015009380863, 'fraction_numerical': 0.03330206378986867, 'mean_word_length': 4.827868852459017, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Evaluation of bcl-2 protein expression in the normal mammary epithelium of premenopausal women treated with raloxifene.

CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts

Abstract #5087 

Background: Bcl-2 is one of the most important blockers of cell death and therapeutic strategies to reduce its expression may be useful in breast cancer chemoprevention. The aim of this study was to evaluate the expression of the bcl-2 protein in the normal breast tissue of premenopausal women. Materials and Methods: Thirty ovulatory premenopausal women of 18 to 40 years of age, who had been diagnosed fibroadenoma of the breast participated of this study. This was a randomized, double-blind, placebo controlled study. Patiens were randomized into two groups: Group A (placebo, n=16) and Group B (raloxifene, n=14). The drug was administered in the dose of 60 mg/day for 22 days, beginning on the first day of menstrual cycle. Excision of fibroadenoma was carried out on the 23rd day during which a sample of normal breast tissue was collected for immunohistochemistry. Cells in which cytoplasm was intensely stained in brown by anti-bcl-2 antibody were considered positive for bcl-2. A number of 500 cells on each slide were counted using a light microscope (400x), beginning with the area in which there was the greatest expression of bcl-2. The percentage of stained cells for each case was obtained from the ratio between the number of cells with stained cytoplasm and total of cells multiplied by 100. Student's t test was used to compare the means of percentages of stained cytoplasms in the two groups (p<0.05). Results: There was a significant reduction in the mean percentage of bcl-2-stained cytoplasms in the group that received raloxifene compared to the placebo group, 10.90±2.11 and 19.05±2.36, respectively (p<0.017). Discussion: Our results indicate that raloxifene reduces the anti-apoptotic bcl-2 protein expression in the normal breast tissue of premenopausal women reinforcing the argument for its use in chemoprevention of breast cancer.

Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5087.